The restricted binding repertoire of Bcl-B leaves Bim as the universal BH3-only prosurvival Bcl-2 protein antagonist

Cell Death and Disease

Volumn 3, Issue 12, 2012, Pages

  Rautureau, G J P ^a,d   Yabal, M ^a,e   Yang, H ^a   Huang, D C S ^a   Kvansakul, M ^a,b   Hinds, M G ^a,c  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b LA TROBE UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITÉ DE LYON   (France)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

apoptosis; Bcl 2 family; Bcl B; Bcl 2L10; BH3 only; protein structure

Indexed keywords

BCL B PROTEIN; BH3 PROTEIN; BIK PROTEIN; BIM PROTEIN; CARRIER PROTEIN; ONCOPROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; UNCLASSIFIED DRUG;

ALPHA HELIX; ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BINDING AFFINITY; CELL ASSAY; CELL SURVIVAL; CELL VIABILITY; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; SEQUENCE ANALYSIS;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE; CELL SURVIVAL; HUMANS; MEMBRANE PROTEINS; MICE; MOLECULAR CONFORMATION; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SEQUENCE ALIGNMENT;

EID: 84871235883     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.178     Document Type: Article

References (60)

1. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47-59.
2. Hinds MG, Day CL. Regulation of apoptosis: uncovering the binding determinants. Curr Opin Struct Biol 2005; 15: 690-699.
3. Willis SN, Adams JM. Life in the balance: how BH3-only proteins induce apoptosis. Curr Opin Cell Biol 2005; 17: 617-625.
4. Ke N, Godzik A, Reed JC. Bcl-B, a novel Bcl-2 family member that differentially binds and regulates Bax and Bak. J Biol Chem 2001; 276: 12481-12484.
5. Zhang H, Holzgreve W, De Geyter C. Bcl2-L-10, a novel anti-apoptotic member of the Bcl-2 family, blocks apoptosis in the mitochondria death pathway but not in the death receptor pathway. Hum Mol Genet 2001; 10: 2329-2339.
6. Aouacheria A, Arnaud E, Venet S, Lalle P, Gouy M, Rigal D et al. Nrh, a human homologue of Nr-13 associates with Bcl-Xs and is an inhibitor of apoptosis. Oncogene 2001; 20: 5846-5855.
7. Aouacheria A, Brunet F, Gouy M. Phylogenomics of life-or-death switches in multicellular animals: Bcl-2, BH3-Only, and BNip families of apoptotic regulators. Mol Biol Evol 2005; 22: 2395-2416.
8. Rautureau GJ, Day CL, Hinds MG. The structure of Boo/Diva reveals a divergent Bcl-2 protein. Proteins 2010; 78: 2181-2186.
9. Huang DC, Strasser A. BH3-only proteins-essential initiators of apoptotic cell death. Cell 2000; 103: 839-842.
10. Feng CY, Rise ML. Characterization and expression analyses of anti-apoptotic Bcl-2-like genes NR-13, Mcl-1, Bcl-X1, and Bcl-X2 in Atlantic cod (Gadus morhua). Mol Immunol 2010; 47: 763-784.
11. Zhai D, Jin C, Huang Z, Satterthwait AC, Reed JC. Differential regulation of Bax and Bak by anti-apoptotic Bcl-2 family proteins Bcl-B and Mcl-1. J Biol Chem 2008; 283: 9580-9586.
12. Inohara N, Gourley TS, Carrio R, Muniz M, Merino J, Garcia I et al. Diva, a Bcl-2 homologue that binds directly to Apaf-1 and induces BH3-independent cell death. J Biol Chem 1998; 273: 32479-32486.
13. Song Q, Kuang Y, Dixit VM, Vincenz C. Boo, a novel negative regulator of cell death, interacts with Apaf-1. EMBO J 1999; 18: 167-178.
14. Russell HR, Lee Y, Miller HL, Zhao J, McKinnon PJ. Murine ovarian development is not affected by inactivation of the bcl-2 family member diva. Mol Cell Biol 2002; 22: 6866-6870.
15. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
16. Mehlen P, Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer 2006; 6: 449-458.
17. Amundson SA, Myers TG, Scudiero D, Kitada S, Reed JC, Fornace AJ Jr. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res 2000; 60: 6101-6110.
18. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010; 463: 899-905.
19. Lee R, Chen J, Matthews CP, McDougall JK, Neiman PE. Characterization of NR13-related human cell death regulator, Boo/Diva, in normal and cancer tissues. Biochim Biophys Acta 2001; 1520: 187-194.
20. Zhai D, Ke N, Zhang H, Ladror U, Joseph M, Eichinger A et al. Characterization of the antiapoptotic mechanism of Bcl-B. Biochem J 2003; 376: 229-236.
21. Luciano F, Krajewska M, Ortiz-Rubio P, Krajewski S, Zhai D, Faustin B et al. Nur77 converts phenotype of Bcl-B, an antiapoptotic protein expressed in plasma cells and myeloma. Blood 2007; 109: 3849-3855.
22. Beverly LJ, Varmus HE. MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family. Oncogene 2009; 28: 1274-1279.
23. Yasui K, Mihara S, Zhao C, Okamoto H, Saito-Ohara F, Tomida A et al. Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res 2004; 64: 1403-1410.
24. Aouacheria A, Banyai M, Rigal D, Schmidt CJ, Gillet G. Characterization of vnr-13, the first alphaherpesvirus gene of the bcl-2 family. Virology 2003; 316: 256-266.
25. Lalle P, Aouacheria A, Dumont-Miscopein A, Jambon M, Venet S, Bobichon H et al. Evidence for crucial electrostatic interactions between Bcl-2 homology domains BH3 and BH4 in the anti-apoptotic Nr-13 protein. Biochem J 2002; 368: 213-221.
26. Krajewska M, Kitada S, Winter JN, Variakojis D, Lichtenstein A, Zhai D et al. Bcl-B expression in human epithelial and nonepithelial malignancies. Clin Cancer Res 2008; 14: 3011-3021.
27. Yip KW, Godoi PH, Zhai D, Garcia X, Cellitti JF, Cuddy M et al. A TR3/Nur77 peptide-based high-throughput fluorescence polarization screen for small molecule Bcl-B inhibitors. J Biomol Screen 2008; 13: 665-673.
28. Gavathiotis E, Suzuki M, Davis ML, Pitter K, Bird GH, Katz SG et al. BAX activation is initiated at a novel interaction site. Nature 2008; 455: 1076-1081.
29. Day CL, Chen L, Richardson SJ, Harrison PJ, Huang DC, Hinds MG. Solution structure of prosurvival Mcl-1 and characterization of its binding by proapoptotic BH3-only ligands. J Biol Chem 2005; 280: 4738-4744.
30. Day CL, Smits C, Fan FC, Lee EF, Fairlie WD, Hinds MG. Structure of the BH3 domains from the p53-inducible BH3-only proteins Noxa and Puma in complex with Mcl-1. J Mol Biol 2008; 380: 958-971.
31. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-681.
32. Lee EF, Czabotar PE, van Delft MF, Michalak EM, Boyle MJ, Willis SN et al. A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation. J Cell Biol 2008; 180: 341-355.
33. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006; 10: 389-399.
34. Zhai D, Jin C, Satterthwait AC, Reed JC. Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death Differ 2006; 13: 1419-1421.
35. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA et al. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74: 597-608.
36. Zong WX, Lindsten T, Ross AJ, MacGregor GR, Thompson CB. BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes Dev 2001; 15: 1481-1486.
37. Rautureau GJP, Day CL, Hinds MG. Intrinsically disordered proteins in Bcl-2 regulated apoptosis. Int J Mol Sci 2010; 11: 1808-1824.
38. Lanave C, Santamaria M, Saccone C. Comparative genomics: the evolutionary history of the Bcl-2 family. Gene 2004; 333: 71-79.
39. Guillemin Y, Lalle P, Gillet G, Guerin JF, Hamamah S, Aouacheria A. Oocytes and early embryos selectively express the survival factor BCL2L10. J Mol Med 2009; 87 923-940.
40. Yoon SJ, Kim EY, Kim YS, Lee HS, Kim KH, Bae J et al. Role of Bcl2-like 10 (Bcl2l10) in regulating mouse oocyte maturation. Biol Reprod 2009; 81: 497-506.
41. Huang Q, Petros AM, Virgin HW, Fesik SW, Olejniczak ET. Solution structure of the BHRF1 protein from Epstein-Barr virus, a homolog of human Bcl-2. J Mol Biol 2003; 332: 1123-1130.
42. Kvansakul M, Wei AH, Fletcher JI, Willis SN, Chen L, Roberts AW et al. Structural basis for apoptosis inhibition by Epstein-Barr virus BHRF1. PLoS Pathogen 2010; 6: e1001236.
43. Kvansakul M, van Delft MF, Lee EF, Gulbis JM, Fairlie WD, Huang DC et al. A structural viral mimic of prosurvival Bcl-2: a pivotal role for sequestering proapoptotic Bax and Bak. Mol Cell 2007; 25: 933-942.
44. Kvansakul M, Yang H, Fairlie WD, Czabotar PE, Fischer SF, Perugini MA et al. Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands. Cell Death Differ 2008; 15: 1564-1571.
45. Lee RM, Gillet G, Burnside J, Thomas SJ, Neiman P. Role of Nr13 in regulation of programmed cell death in the bursa of Fabricius. Genes Dev 1999; 13: 718-728.
46. Cluzeau T, Robert G,Mounier N, Karsenti JM, DufiesM, Puissant A et al. BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients. Oncotarget 2012; 3: 490-501.
47. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005; 5: 876-885.
48. Rudin CM, Hann CL, Garon EB, Ribeiro de Oliveira M, Bonomi PD, Camidge DR et al. Phase 2 Study of single agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res 2012; 18: 3163-3169.
49. Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 2011; 29: 909-916.
50. Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010; 11: 1149-1159.
51. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 2011; 28: 2731-2739.
52. Krissinel E, Henrick K. Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. Acta Crystallogr D 2004; 60: 2256-2268.
53. Lu GG. TOP: a new method for protein structure comparisons and similarity searches. J Appl Crystallogr 2000; 33: 176-183.
54. Guillemin Y, Cornut-Thibaut A, Gillet G, Penin F, Aouacheria A. Characterization of unique signature sequences in the divergent maternal protein Bcl2l10. Mol Biol Evol 2011; 28: 3271-3283.
55. Marley J, Lu M, Bracken C. A method for efficient isotopic labeling of recombinant proteins. J Biomol NMR 2001; 20: 71-75.
56. Berne PF, Doublie S, Carter CW. Molecular biology for structural biology. In: Ducruix A, Giege R (eds.) Crystallization of Nucleic Acids and Proteins. A Practical Approach. Oxford University Press: Oxford, 1999. pp 45-73.
57. Kinsella TM, Nolan GP. Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Hum Gene Ther 1996; 7: 1405-1413.
58. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005; 17: 393-403.
59. Wilson-Annan J, O'Reilly LA, Crawford SA, Hausmann G, Beaumont JG, Parma LP et al. Proapoptotic BH3-only proteins trigger membrane integration of prosurvival Bcl-w and neutralize its activity. J Cell Biol 2003; 162: 877-887.
60. Kuwana T, Bouchier-Hayes L, Chipuk JE, Bonzon C, Sullivan BA, Green DR et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 2005; 17: 525-535.